Jiangsu Hengrui Medicine and Shanghai Hengrui Pharmaceutical prepare and test RIPK1 inhibitors
Oct. 13, 2023
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have described fused heterocyclic compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors.